Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MPO | P05164 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.63 |
| ▸ | ACE | P12821 | 3/20 | 0.59 |
| ▸ | ECE1 | P42892 | 6/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3547828 | 1.00 | KDM4E (0.64) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL29405435 | 1.00 | KDM4E (0.64) | KDM4EMEN1LMNAMPOMAPT | |
| Hydrochloric Acid SCHEMBL7623258 | 0.99 | KDM4E (0.62) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL29844860 | 0.97 | ERAP2 (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL29384524 | 0.95 | ERAP2 (0.68) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL29406957 | 0.94 | ERAP2 (0.60) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL31215421 | 0.94 | ERAP2 (0.67) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL29350328 | 0.93 | ERAP2 (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL30291156 | 0.92 | KDM4E (0.59) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL16565972 | 0.92 | KDM4E (0.59) | KDM4EMEN1LMNAMPOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854792-B1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-12-26 | — | — | EP | claimed |
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-01-29 | — | — | US | claimed |
| EP-1854792-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-14 | — | — | EP | claimed |
| US-20180314790-A1 | System, Method and Apparatus for Determining the Effect of Genetic Variants | METABOLON, INC. | 2018-11-01 | — | — | US | disclosed |
| US-20170276669-A1 | PRECISE ESTIMATION OF GLOMERULAR FILTRATION RATE FROM MULTIPLE BIOMARKERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-09-28 | — | — | US | disclosed |
| EP-3215633-A1 | SYSTEM, METHOD AND APPARATUS FOR DETERMINING THE EFFECT OF GENETIC VARIANTS | Metabolon, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| CN-106795186-A | The preparation method of morpholino oligonucleotide | 味之素株式会社 | 2017-05-31 | — | — | CN | disclosed |
| WO-2016073547-A1 | SYSTEM, METHOD AND APPARATUS FOR DETERMINING THE EFFECT OF GENETIC VARIANTS | METABOLON, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20140343865-A1 | Biomarkers for Kidney Cancer and Methods Using the Same | METABOLON, INC. | 2014-11-20 | — | — | US | disclosed |
| EP-2788763-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| CN-102477068-B | Amino acid derivative for preparing thrombus dissolving medicament, and preparation method and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2013-07-24 | — | — | CN | disclosed |
| WO-2013086365-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-1854792-B1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-12-26 | — | — | EP | disclosed |
| CN-102477068-A | Amino acid derivative for preparing thrombus dissolving medicament, and preparation method and application thereof | UNIV CAPITAL MEDICAL | 2012-05-30 | — | — | CN | disclosed |
| US-7820693-B2 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1854792-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | NQO1, NR5A1, SRD5A1 | KDM4E 3057/4885MEN1 2133/4885LMNA 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.